Innoviva EBITDA Margin 2010-2024 | INVA

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Innoviva (INVA) over the last 10 years. The current EBITDA margin for Innoviva as of March 31, 2024 is .
Innoviva EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-03-31 $0.31B $0.15B 48.23%
2023-12-31 $0.31B $0.15B 49.03%
2023-09-30 $0.29B $0.15B 52.76%
2023-06-30 $0.29B $0.40B 138.62%
2023-03-31 $0.32B $0.45B 142.59%
2022-12-31 $0.33B $0.50B 149.85%
2022-09-30 $0.37B $0.58B 154.42%
2022-06-30 $0.40B $0.38B 93.81%
2022-03-31 $0.40B $0.39B 99.24%
2021-12-31 $0.39B $0.40B 101.02%
2021-09-30 $0.38B $0.38B 100.53%
2021-06-30 $0.37B $0.37B 100.27%
2021-03-31 $0.34B $0.35B 100.58%
2020-12-31 $0.34B $0.34B 101.48%
2020-09-30 $0.32B $0.33B 102.48%
2020-06-30 $0.30B $0.31B 102.00%
2020-03-31 $0.29B $0.29B 101.40%
2019-12-31 $0.26B $0.27B 101.53%
2019-09-30 $0.27B $0.27B 101.13%
2019-06-30 $0.26B $0.27B 101.92%
2019-03-31 $0.26B $0.27B 102.27%
2018-12-31 $0.26B $0.26B 99.23%
2018-09-30 $0.25B $0.25B 99.20%
2018-06-30 $0.24B $0.23B 97.06%
2018-03-31 $0.23B $0.22B 93.48%
2017-12-31 $0.22B $0.20B 92.66%
2017-09-30 $0.19B $0.17B 89.58%
2017-06-30 $0.18B $0.16B 90.34%
2017-03-31 $0.15B $0.14B 91.95%
2016-12-31 $0.13B $0.13B 94.74%
2016-09-30 $0.11B $0.11B 93.75%
2016-06-30 $0.09B $0.09B 92.47%
2016-03-31 $0.07B $0.07B 91.67%
2015-12-31 $0.06B $0.05B 89.09%
2015-09-30 $0.04B $0.03B 84.62%
2015-06-30 $0.03B $0.02B 57.69%
2015-03-31 $0.02B $-0.00B -6.25%
2014-12-31 $0.01B $-0.02B -212.50%
2014-09-30 $0.00B $-0.00B 0.00%
2014-06-30 $0.00B $-0.00B -100.00%
2014-03-31 $0.00B 0 0.00%
2013-12-31 $0.00B $-0.02B -666.67%
2013-09-30 $0.01B $-0.07B -875.00%
2013-06-30 $0.01B $-0.10B -1055.56%
2013-03-31 $0.01B $-0.12B -1377.78%
2012-12-31 $0.14B $-0.01B -3.70%
2012-09-30 $0.13B $-0.01B -7.46%
2012-06-30 $0.14B $-0.01B -4.32%
2012-03-31 $0.14B $0.01B 4.17%
2011-12-31 $0.02B $-0.10B -443.48%
2011-09-30 $0.03B $-0.09B -340.00%
2011-06-30 $0.02B $-0.08B -316.67%
2011-03-31 $0.02B $-0.07B -300.00%
2010-12-31 $0.02B $-0.07B -300.00%
2010-09-30 $0.02B $-0.08B -357.14%
2010-06-30 $0.02B $-0.08B -350.00%
2010-03-31 $0.02B $-0.08B -376.19%
2009-12-31 $0.03B $-0.08B -304.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.013B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27